Validating Novel, Non-contrast Cardiac MRI Imaging in Haemodialysis Patients

Launched by UNIVERSITY OF LEICESTER · Jul 2, 2018

Keywords

ClinConnect Summary

This clinical trial is exploring a new type of heart imaging called native T1 mapping, which may help doctors better understand the level of scarring in the hearts of patients with advanced kidney disease who are on dialysis. Currently, there aren’t effective ways to measure this scarring, and the study aims to see how accurately this new MRI technique can reflect the actual condition of the heart in these patients.

To participate in the trial, individuals must be on dialysis for at least three months and expected to live no longer than a year. They must be able to understand and give consent for the study and agree to donate their heart for research after passing away. However, those with certain conditions that prevent them from having an MRI, or who cannot provide informed consent, are not eligible. Participants will undergo cardiac MRI scans and will be monitored closely, contributing to important research that could improve care for future patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Prevalent haemodialysis patient (more than 3 months)
• • Active on the supportive care register with anticipated death in the subsequent 12 months
• • Able to give informed consent
• • Consent to donation of heart for research following death
• • Able to understand written and verbal explanations in English
• Exclusion Criteria:
• • Contraindication to MRI scan (e.g. pacemaker, incompatible metallic implants, claustrophobia)
• • Patients with expected or potential infiltrative cardiomyopathy (e.g. amyloidosis)
• • Unable to give informed consent
• • Unable to understand written and verbal explanations in English